EZH2 and follicular lymphoma: Tazemetostat (EPZ-6438) is an oral, first-in-class, selective small-molecule EZH2 inhibitor, which has been approved by FDA to treat adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation and who have received at least 2 prior systemic therapies, or those who have no optimal alternative treatment options.